<Blinded Review: TIME_ANON_0743>
**Composite Score:** 6.5 / 10.0 (Rigor: 2.0/3.5 | Claims: 1.6/2.5 | Biology: 1.4/2.0 | Reproducibility: 1.5/2.0)
**Scientific Core Score:** 5.0 / 8.0
**Bias Category:** Technical/Assay
**Verdict:** Major Revision
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Mature/Classical
**Epistemic Stage:** Clinical/Observational

OVERALL_SCORE: 6.5/10
VERDICT: CAVEATS
ESTIMATED_DECADE: 2000s

---

### 1. Executive Summary (SUMMARY)
This concise clinical genetics study uses human–mouse phylogenetic footprinting (`ECR Browser`/`rVista v2.0` and `ConSite`/`JASPAR`, requiring $\ge 70\%$ identity over 100 bp across 3 kb upstream of the *STK11/LKB1* translation start codon) to delineate a conserved upstream putative regulatory region (`-1090` to `-1472`) and screens 33 Peutz-Jeghers syndrome (`PJS`) patients lacking coding or large-deletion mutations in *STK11/LKB1* via bidirectional Sanger sequencing and 814-bp PCR gel sizing across nucleotides `-1001` to `-1815`. Three sequence variants (`-1566 G>C` [`rs3795061`], `-1268 G>T`, and `-1709insTdelCC`) were detected in cases, all of which were also found in healthy controls, leading the authors to conclude that *STK11/LKB1* promoter sequence changes are unlikely to account for *STK11*-mutation-negative PJS (upper 95% confidence bound on prevalence $\approx 9\%$). While the study is a useful and well-executed negative screen of the distal conserved element, it leaves the entire proximal 1,000 bp (`-1` to `-1000`, containing the 5'-UTR and core promoter) unsequenced and contains an arithmetic error in the reported genotype counts for `-1268 G>T`.

### 2. Methodological & Statistical Audit (STRENGTHS & WEAKNESSES & METHODOLOGICAL AUDIT)
**Strengths:**
- **Pre-Screened Clinical Cohort & Appropriate Binomial Confidence Bound:** All 33 PJS probands met established diagnostic criteria and had previously been excluded for coding, splice-site, and large-scale exonic deletions in *STK11/LKB1*. Observing $0/33$ pathogenic variants is appropriately contextualized with its exact upper 95% binomial confidence bound ($\approx 9\%$ prevalence, `line 39`).
- **Control Verification for Novel Indel:** The novel `-1709insTdelCC` variant found in 1 PJS patient was screened across $n = 92$ healthy controls by dHPLC (`WAVE`), identifying 1 carrier (`1/92`) and excluding it as a high-penetrance PJS allele.

**Weaknesses & Methodological Flaws:**
- **Arithmetic Error in Genotype Counts (`line 32`):** In Results and Discussion (`line 32`), the authors state: *"An additional single nucleotide change at position -1268 (G -> T) was identified in **eight cases (seven heterozygotes and four homozygotes)**."* Seven heterozygotes plus four homozygotes equals **11 cases**, not 8 cases.
- **Omission of the Proximal Core Promoter and 5'-UTR (`-1` to `-1000` bp):** Because nucleotide `0` was defined at the *STK11* translation initiation codon (`line 25`) and the phylogenetic footprinting filter required $\ge 70\%$ human–mouse identity over 100 bp, the sequenced amplicons (`P1`–`P3`) only covered nucleotides **`-1001` to `-1815` (`814 bp`)**. Consequently, the entire proximal 1 kb immediately upstream of the translation start site (`-1` to `-1000`, encompassing the 5'-UTR and proximal CpG-island core promoter where basal transcriptional machinery binds) was never sequenced in the 33 patients. Concluding broadly that *"promoter sequence changes are unlikely to contribute to PJS"* (`Abstract line 11`) without screening the proximal `-1` to `-1000` region overstates the completeness of the promoter screen.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **Claim 1:** *Nucleotides -1090 to -1472 upstream of the STK11 translation start site exhibit high human–mouse sequence conservation and dense predicted transcription factor binding sites.* `[Well Supported]` — Concordantly identified by `ECR Browser`/`rVista`, `ConSite`, `Proscan v1.7`, and `Transplorer` (`Figure 1`).
- **Claim 2:** *Pathogenic sequence variants or small indels within the conserved -1001 to -1815 upstream region of STK11/LKB1 are unlikely to account for >9% of STK11-negative PJS cases.* `[Well Supported]` — Directly supported by bidirectional Sanger sequencing and 814-bp PCR gel analysis across 33 probands.
- **Claim 3:** *Promoter mutations in STK11/LKB1 as a whole are unlikely to cause PJS.* `[Moderately Supported]` / `[Fragile]` — Only the distal conserved region (`-1001` to `-1815`) was sequenced, leaving the proximal `-1` to `-1000` core promoter untested.

### 4. Reproducibility & Data Completeness
- **Strengths:** Reference contig accession (`NT_011255`), exact nucleotide numbering convention (`0 = translation start`), all 6 PCR/sequencing primer sequences (`P1Fwd/Rev, P2Fwd/Rev, P3Fwd/Rev`), and software versions (`rVista v2.0`, `Proscan v1.7`, `BigDye v3.1`) are fully reported.
- **Weaknesses:** The arithmetic discrepancy in the `-1268 G>T` genotype counts (`8` total vs. `7 het + 4 hom`) needs correction.
</Blinded Review: TIME_ANON_0743>
